Sofinnova Venture Partners — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)
Board seatAnand Mehra· per SEC Form D · $11.4M raise · filed Apr 2020
Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more
BiotechHamilton
Brenton K. Ahrens(Director)James I. Healy(Director)Mark Chin(Director)Patrick J. Heron(Director)inRonald M. Hunt(Director)Shahzad Malik(Director)
Board seatJames I. Healy· per SEC Form D · $51.6M raise · filed Jan 2020
Co-investorsFrazier Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.